Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.

Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J.

Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75. Erratum in: Cancer Chemother Pharmacol. 2008 Jan;61(1):177.

PMID:
17440727
2.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
3.

[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].

Honda K, Fukuhara T, Kojima Y, Tanaka H, Kushihata F, Kobayashi N.

Gan To Kagaku Ryoho. 2006 Dec;33(13):2089-92. Japanese.

PMID:
17197760
4.

Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.

Kruth J, Nissen J, Ernst T, Kripp M, Lukan N, Merx K, Hofmann WK, Hochhaus A, Hofheinz RD.

J Cancer Res Clin Oncol. 2010 Dec;136(12):1845-51. doi: 10.1007/s00432-010-0843-6.

PMID:
20224968
5.

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).

Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E.

Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23. doi: 10.1007/s00280-011-1680-2.

PMID:
21626049
6.

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.

Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM.

Cancer Chemother Pharmacol. 2014 Apr;73(4):839-45. doi: 10.1007/s00280-014-2414-z.

PMID:
24562589
7.

[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].

Wang XX, Zhou ZM, Yuan ZY, Zhang DS, Shi YX, Jiang WQ.

Ai Zheng. 2007 Apr;26(4):407-10. Chinese.

PMID:
17430662
8.

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.

Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J 3rd, Gibbs J, Iyer R.

Br J Cancer. 2009 Jun 16;100(12):1842-5. doi: 10.1038/sj.bjc.6605099.

9.

Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.

Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8. doi: 10.1007/s00280-010-1329-6.

PMID:
20428874
10.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Saif MW, Syrigos K, Penney R, Kaley K.

Anticancer Res. 2010 Jul;30(7):2905-9.

PMID:
20683031
11.

Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.

Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS.

Oncology. 2009;76(5):333-7. doi: 10.1159/000209962.

PMID:
19307739
12.

The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.

Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR.

Cancer Chemother Pharmacol. 2012 Feb;69(2):425-30. doi: 10.1007/s00280-011-1705-x.

13.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE.

J Clin Oncol. 2005 Nov 1;23(31):8033-40.

PMID:
16258101
14.

A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.

Lee JJ, Han JY, Lee DH, Kim HY, Chun JH, Lee HG, Yoon SM, Lee SY, Lee JS.

Jpn J Clin Oncol. 2006 Dec;36(12):761-7.

PMID:
17043059
15.

A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.

De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr.

Cancer Chemother Pharmacol. 2012 Feb;69(2):415-24. doi: 10.1007/s00280-011-1704-y.

16.

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.

Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, Zhan F, Asmar L, Myrand SP, Hozak RR, Zhao L, Gill JF, Mullaney BP, Obasaju CK, Nicol SJ.

Invest New Drugs. 2011 Feb;29(1):144-53. doi: 10.1007/s10637-009-9307-8.

PMID:
19714296
17.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

18.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
19.

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV.

Ann Oncol. 2003 Jan;14(1):97-104.

PMID:
12488300
20.

A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.

Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, Zalupski M, Hejna G, Bekaii-Saab T.

Cancer Chemother Pharmacol. 2011 Mar;67(3):511-7. doi: 10.1007/s00280-010-1348-3.

PMID:
20461379

Supplemental Content

Support Center